

Supplemental Information

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGF β pathway genes through histone deacetylation

**Makoto Saika¹, Daichi Inoue^{1,2}, Reina Nagase¹, Naru Sato¹, Akiho Tsuchiya¹,
Tomohiro Yabushita¹, Toshio Kitamura^{1*}, Susumu Goyama^{1*}**

¹Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan


²(current address) Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Supplemental Figure 1

Supplemental Figure 2

Supplemental Figure 3

Supplemental Figure 1



Supplemental Figure 1.


(a) Western blotting for histone acetylation in 32D cells and cSAM cells. Vorinostat increased H3K8ac and H4K16ac in cSAM cells. Full-length blots are shown in Supplemental Figure 2.

(b, c) Genomic DNA fragments from bone marrow c-kit+ cells and cSAM cells cultured with 1 μ M vorinostat or vehicle control (DMSO) were immunoprecipitated with anti-H4K8ac (b) and anti-H4K16ac (c) antibodies. Enrichments of H3K14ac and H4K16ac at transcription starting sites of Tgfr1, Tgfr2, Tgfr3, Smad1, Smad3, and Smad4 were measured by qPCR. Data are shown as mean \pm s.e.m.


* $P < 0.05$, ** $P < 0.01$, Student t-test.

Supplemental Figure 2

Full blots for Figure 2b & Supplemental Figure 1



Full blots for Figure 3c



Supplemental Figure 3

Full blots for Figure 6a

